

Microsoft Bing

国内版 国际版

Therapy-related myeloid leukemia during erlotinib treatment in an

66,400 Results

Any time

ALL

IMAGES

VIDEOS

Therapy-Associated Myeloid Dysplasia in a Long-Surviving ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981410>

Cited by: 1

Author: Jillian Suzukida, Kristin Kaley, Azra Raza,...

Publish Year: 2016

Therapy-related MDS accounts for 10%–20% of cases of MDS or acute myelogenous leukemia (AML). For our patient, the latency period to developing t-MDS was about seven years. The chronological...

[PDF] A Pilot Phase II Study of Erlotinib for the Treatment of ...

https://clinicaltrials.gov/ProvidedDocs/97/NCT01664897/Prot_SAP_000.pdf

Two additional phase 3 clinical trials of erlotinib have been completed in NSCLC patients: • First-line treatment of NSCLC, concurrently administered in combination with carboplatin/peclitaxel (Study...

A phase I/II trial of Erlotinib in higher risk ...

<https://www.sciencedirect.com/science/article/pii/S0145212614002963>

Chat with Bing

Sign in

See results for

Gefitinib (Drug)

Gefitinib is used to treat lung cancer.

Myelodysplastic Syndrome (Medical Condition)

A group of disorders resulting from poorly formed or dysfunctional blood cells.

Search Tools

Turn off Hover Translation (关闭翻译)

https://cn.bing.com/?FORM=Z9FD1

Microsoft Bing

国内版

国际版

Therapy-related myeloid leukemia during erlotinib treatment in an r

🗨️

📄

🔍

Sign in

☰

ALLIMAGESVIDEOS

47,900 ResultsAny time ▾

Erlotinib in a Patient With Acute Myelogenous Leukemia and ...

<https://ascopubs.org/doi/10.1200/JCO.2008.17.0357>

Sep 21, 2016 - Finally, notwithstanding, a recently published case report provides further clinical evidence for the therapeutic efficacy of erlotinib in EGFR-negative myeloid malignancies. 8 The case of our patient points out the importance of the presence of L858R mutation within the kinase domain of EGFR as a predictive factor in determining the response to erlotinib, even if the most relevant aspect of our case is the unexpected antineoplastic activity of erlotinib on ...

Cited by: 28Author: Vincenzo Pilini, Carmela Aringo, Giusepp...

Publish Year: 2008

Therapy-Associated Myeloid Dysplasia in a Long-Surviving ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981410>

Jul 13, 2016 - Therapy-related MDS accounts for 10%-20% of cases of MDS or acute myelogenous leukemia (AML). For our patient, the latency period to developing t-MDS was about seven years. The chronological association of prior chemotherapy regimens administered in this patient as well as the cytogenetic analysis showing chromosomes 5 and 7 abnormalities support the diagnosis of treatment ...

Cited by: 1Author: Jillian Suzukida, Kristin Kaley, Azra Raza,...

Publish Year: 2016

PEOPLE ALSO ASK

Is there a cure for non small cell lung cancer? ▾

What are the prognostic factors for acute myeloid leukemia? ▾

Search Tools

Turn off Hover Translation (关闭翻译)

国内版 国际版

Therapy-related myeloid leukemia during erlotinib treatment in a r



ALL IMAGES VIDEOS

49,200 Results

Any time ▾

Erlotinib in a Patient With Acute Myelogenous Leukemia and ...

<https://ascopubs.org/doi/10.1200/JCO.2008.17.0357>

Sep 21, 2016 · Finally, noteworthy, a recently published case report provides further clinical evidence for the therapeutic efficacy of erlotinib in EGFR-negative myeloid malignancies. 8 The case of our patient points out the importance of the presence of L858R mutation within the kinase domain of EGFR as a predictive factor in determining the response to erlotinib, even if the most relevant aspect of our case is the unexpected antineoplastic activity of erlotinib on ...

Cited by: 28

Author: Vincenzo Pitini, Carmela Arrigo, Giusepp...

Publish Year: 2008

Dose-Dependent Mutation Rates Determine Optimum ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633116>

Nov 04, 2015 · Agents such as erlotinib used for EGFR-mutant non-small cell lung cancer or imatinib for chronic myeloid leukemia, for instance, lead to rapid tumor responses. Unfortunately, however, resistance often emerges and renders these agents ineffective after a variable amount of time.

Cited by: 19

Author: Lin L. Liu, Fei Li, William Pao, Franziska ...

Publish Year: 2015

PEOPLE ALSO ASK

What are the treatment options for acute myeloid leukemia? ▾

Which is an inferior outcome for acute myeloid leukemia? ▾

How often is lung cancer non small cell cured? ▾

How many people have been cured of acute lymphoblastic leukemia? ▾

Feedback

Acute Myeloid Leukemia Treatment (PDQ®)—Health ...

<https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq> ▾

Jun 22, 2021 · The treatment of patients with acute myeloid leukemia (AML) is based on whether the